home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 02/12/26

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
AIM - AIM ImmunoTech Announces Commencement of Rights Offering

OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the...

AIM - AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Live video webcast on Wednesday, February 11 th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”), today that it will participate in the Corporate Connect Webinar Ser...

AIM - AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen ® (rintatol...
AIM - Pricey healthcare stocks with halting momentum - low momentum and high valuation

2026-02-03 14:23:14 ET More on AIM ImmunoTech, State Street Health Care Select Sector SPDR ETF, etc. CMS Rates Proposal Shatters Health Insurance Stocks: What Investors Must Know (& Do) Insurers Brace For Extended 'Managed Retreat' Following 2027 MA Proposal XLV ...

AIM - AI-Media to Showcase Real-Time Translation and Accessibility Workflows at ISE 2026 as Multilingual AV Demand Accelerates

BARCELONA, Spain, Jan. 29, 2026 (GLOBE NEWSWIRE) -- AI-Media, a global leader in AI-powered subtitling and language solutions, will be at  ISE 2026 to demonstrate how real-time translation, captioning, and audio description are becoming essential capabilities across professional AV environm...

AIM - AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) –  AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, im...
AIM - AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune ...

AIM - AIM ImmunoTech Announces Stock Dividend

OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --   AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of c...

AIM - Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 16, 2025 /CNW/ -- USANewsGroup.com   News Commentary – Gastrointestinal cancers that once re...
Previous 10 Next 10